From Design to Delivery: A Translational Framework for Non-Viral Gene Editing
The rapid expansion of genomic medicine has intensified the need for scalable, regulatory-aligned and high-fidelity gene editing workflows that can efficiently transition from discovery to clinical evaluation. Aldevron and Integrated DNA Technologies (IDT) are at the forefront of a non-viral gene editing framework designed to support programs across in vivo and ex vivo therapeutic modalities. Emphasis is placed on editing specificity, off-target assessment and manufacturability to support IND-enabling studies.
In this webinar, you will be able to:
- Map a non-viral CRISPR-mediated gene editing workflow to support in vivo and ex vivo genomic medicine applications.
- Understand manufacturability and quality constraints needed to ensure consistency, traceability and IND readiness for complex editing components.
- Integrate off target safety profiling, analytical services and regulatory expectations into an evidence package that supports non viral gene editing IND filings.
Speakers
Ashley Jacobi, Director, Applications & Market Development, Integrated DNA Technologies (IDT)
Headshot & Bio (50-80 words): Ashley received her Molecular Genetics & Biochemistry degree from Cornell College in 2006 and has spent the last 20 years in several roles within the Research & Product Development teams at IDT. She has conducted research in RNAi and antisense oligo technologies, and more recently focused on studying CRISPR gene editing. Ashley is also a certified practitioner in Customer Insight and leads external scientific collaborations at IDT.
IDT custom guide RNAs and CRISPR off-target solutions: early research to therapeutic development
Max Sellman, Senior Product Manager, Aldevron
Headshot & Bio (50-80 words): Max Sellman is Senior Product Manager, Gene Editing, at Aldevron focusing on gene editing protein products and custom services since 2017. He partners closely with research and translational-phase clients to ensure they have the right tools and insights to drive successful therapeutic development. Max holds a bachelor’s degree from the University of Wisconsin in Genetics and Life Sciences Communication.
Enabling production of next-generation genetic medicines through comprehensive CRISPR manufacturing solutions
gatedform
gatedform
546005641
non-viral-gene-editing-wbn
add
Other
promotion
https://lifesciences.danaher.com/
https://help.salesforce.com/s/articleView?id=sf.mc_es_demanager.htm